AstraZeneca said today its vaccine for the novel coronavirus, developed along with the University of Oxford, showed an average efficiency of 70% in protecting against the virus in two study segments. A press note released by the Oxford University stated, "Phase 3 interim analysis including 131 Covid-19 cases indicates that the vaccine is 70.4% effective when combining data from two dosing regimens". The company in a press release said, "Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19."
"One dosing regimen shows vaccine efficacy of 90% when AZD1222 was given as half dose, followed by full dose at least a month apart. Second dosing regimen shows 62% efficacy when given two full doses at least a month apart. Combined analysis has average efficacy of 70%," it added.
AstraZeneca said today its vaccine for the novel coronavirus, developed along with the University of Oxford, showed an average efficiency of 70% in protecting against the virus in two study segments. A press note released by the Oxford University stated, "Phase 3 interim analysis including 131 Covid-19 cases indicates that the vaccine is 70.4% effective when combining data from two dosing regimens". The company in a press release said, "Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19."
"One dosing regimen shows vaccine efficacy of 90% when AZD1222 was given as half dose, followed by full dose at least a month apart. Second dosing regimen shows 62% efficacy when given two full doses at least a month apart. Combined analysis has average efficacy of 70%," it added.
11.jpeg)
30.jpeg)
39.jpeg)
101.jpeg)
417.jpeg)
10.jpeg)
40.jpeg)
100.jpeg)
416.jpeg)
